Blood Podcast

In this week's episode we’ll learn more about an experimental regimen for classical Hodgkin lymphoma that combines brentuximab vedotin, nivolumab, and chemotherapy; a possible role for type 1 interferon signaling in developing autoantibodies to red blood cells in sickle cell disease; and how genomic alterations affecting class I human leukocyte antigen molecules may affect patients with cutaneous T-cell lymphoma. Featured Articles:Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphomaIFN-I promotes T-cell–independent immunity and RBC autoantibodies via modulation of B-1 cell subsets in murine SCDGenetic alteration of class I HLA in cutaneous T-cell lymphoma

In this week's episode we'll learn about the role of iron in myelodysplastic syndromes, or MDS. After that: long-term treatment outcomes in immune thrombocytopenia from the STOPAGO study.  Finally, new insights into APL treatment outcomes and prognostic factors from the large-scale Harmony APL project which used ATRA-Arsenic combination therapy.Featured Articles:Genetic iron overload aggravates, and pharmacological iron restriction improves, MDS pathophysiology in a preclinical studyLong-term follow-up of the STOPAGO studyAcute promyelocytic leukemia: long-term outcomes from the HARMONY project

In this week's episode, we’ll learn about the prevalence and impact of dexamethasone dose reductions during triple or quadruple therapy for newly diagnosed multiple myeloma, a conditional knockout mouse model for testing gene therapy in X-linked sideroblastic anemia, and real-world efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.Featured Articles:Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysisAn erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSASafety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Discover the latest advancements in CLL treatment as researchers compare BTK inhibitors, revealing zanubrutinib's promising edge over ibrutinib. Unravel the genetic mysteries behind the rare AnWj-negative blood type, shedding light on its unique characteristics. Finally, explore how CLL cells cleverly adapt to venetoclax therapy, highlighting the crucial roles of BCL-2 and BAFF in their survival. This unique blend of science sheds new light on cancer treatment and genetic research!

Discover how primary resistance mechanisms impact treatments for multiple myeloma and the role of BCMA-targeted bispecific T-cell engagers. Explore the promising effects of emapalumab therapy on pediatric patients with hemophagocytic lymphohistiocytosis undergoing stem cell transplants. Learn about GSDME-mediated pyroptosis and its connection to increased thrombotic risks in patients receiving cancer chemotherapy. This dynamic discussion uncovers significant advancements in hematological therapies and potential new strategies for improving patient outcomes.

In this week's episode, unravelling follicular lymphoma subtypes. Researchers dissect the biological diversity of follicular lymphoma and introduce a new prognostic mode, that could change the way this B-cell neoplasm is subtyped and treated. Then, concerning stroke rate trends in sickle cell disease. A new report shows increasing rates of cerebrovascular events among people with SCD in California. Finally, procoagulant platelet activation promotes venous thrombosis. Investigators report finding procoagulant platelets in the circulation and in thrombi of patients and mice with DVT or PE. Featured Articles:Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significanceRates of strokes in Californians with sickle cell disease in the post-STOP eraProcoagulant platelet activation promotes venous thrombosis

Discover how clonal hematopoiesis influences prognosis in telomere biology disorders, shedding light on cancer risks. Dive into the genetic landscape of extracutaneous juvenile xanthogranulomas, revealing key molecular drivers for treatment options. Learn about the promising clinical trials of teclistamab for those battling relapsed or refractory multiple myeloma, with an emphasis on its safety and efficacy after previous BCMA-targeted therapies. This discussion highlights the intersection of genetics and innovative treatment strategies.

Discover the cutting-edge approach of targeting mutant calreticulin in myeloproliferative neoplasms with the monoclonal antibody INCA033989. Delve into the alarming findings from the CAT-BLED study, revealing the significant bleeding risks cancer patients face during systemic therapy. Lastly, gain insights into updated diagnostic guidelines for familial hemophagocytic lymphohistiocytosis, featuring improved clinical criteria and recommendations for cellular and genetic assays.

In this Review Series episode on T-Cell Lymphomas introduced by Dr. Philippe Armand we’ll hear from Drs. Laurence de Leval, Javeed Iqbal, and Enrica Marchi about their work concerning new treatment practices and insights to various t-cell lymphomas.Click here to view the complete Review Series featured in Volume 144 Issue 18 of Blood.

Explore a revolutionary risk classification scheme for acute myeloid leukemia patients unsuitable for intensive therapy. Discover the promising results of daratumumab combined with chemotherapy for pediatric leukemia, highlighting an impressive 80% overall response rate in T-cell acute lymphoblastic leukemia. Learn about groundbreaking research on genetically engineered platelets that remain viable under standard blood banking conditions, opening doors for innovative clinical applications. Tune in for insights that could reshape treatment strategies!